LEO Pharma Unveils new Scientific Collaboration Strategy
BALLERUP, Denmark, October 3, 2012 /PRNewswire/ –
LEO Pharma has announced plans to establish five long-term, strategic research
collaborations in four countries by the end of next year. The ambitious initiative aims to
deliver new treatment options to dermatology patients – faster than ever before. The first
in the series of collaborations to be announced is with Charite, one of Europe’s oldest
and largest university hospitals.
Today, LEO Pharma has revealed plans to establish five long-term, strategic research
collaborations from now until the end of 2013 in Australia, France, Germany and the US.
The research will supplement LEO Pharma’s internal R&D activities.
Each collaboration will integrate discovery research and exploratory clinical trials
to an exceptionally high degree. The unique approach will enable LEO Pharma to explore
more dermatological treatment solutions at record speed – reducing the time it takes to
deliver new therapeutic options.
“This marks the beginning of an exciting journey for LEO Pharma and the patients we
serve. By joining forces with world-leading experts, we hope to break important, new
ground in dermatology – faster than we’ve ever done before,” says Kim Kjoeller, Senior
Vice President, Global Development.
“We’re entering unchartered territory. Not only will we identify and test treatment
solutions that no one has explored before; we will also explore new therapeutic areas for
LEO Pharma. By working at the forefront of drug discovery and development, LEO Pharma can
go that extra mile to meet patient needs. We are excited about the possibilities ahead.”
The scope of the scientific collaboration strategy covers skin conditions in which LEO
Pharma is already active, such as psoriasis, atopic dermatitis and actinic keratosis, as
well as new therapeutic areas for LEO Pharma.
Exploring itch at joint institute
LEO Pharma can already reveal details of its first collaboration: establishing a joint
institute called I2DEAL, the International Institute of Dermatology and Allergy, with
Charite, one of Europe’s oldest and largest university hospitals. Here, experts will
conduct early exploratory clinical trials and explore the underlying mechanisms of disease
in allergic and itchy skin conditions. It is the first time that the Department of
Dermatology and Allergy at Charite enters into collaboration with a private pharmaceutical
company to such a high degree.
Prof. Dr. Marcus Maurer, Director of Research at the Department of Dermatology and
Allergy at Charite, said: “A perfect match – that’s how I’d describe our partnership with
LEO Pharma. By combining our individual expertise, we can make significant advances in
dermatology research and towards meeting patient needs.
“Our research will focus on itch and inflammation. We know that itchy and inflamed
skin is by far the greatest burden of disease for many patients, particularly those with
eczema and psoriasis. Despite this, patients lack satisfactory treatment options. Together
with LEO Pharma, we aim to discover new ways to relieve patients from itchy and inflamed
Eva Juul Langlands, Corporate Communications Manager, +45-41-88-30-94,
SOURCE LEO Pharma A/S